Disis, M.L., Taylor, M.H., Kelly, K., Beck, J.T., Gordon, M., Moore, K.M., et al. (2019) Efficacy and Safety of Avelumab for Patients with Recurrent or Refractory Ovarian Cancer: Phase 1b Results from the JAVELIN Solid Tumor Trial. JAMA Oncology, 5, 393-401.
https://doi.org/10.1001/jamaoncol.2018.6258

has been cited by the following article:

• TITLE: Research Hotspot and Application Status of Immune Evasion Mechanism in Ovarian Cancer

  AUTHORS: Yuchun Zhang, Hui Wang

  KEYWORDS: Ovarian Cancer, Immune Evasion Mechanism, CD4+ T cells, PD-1/PDL-1, CTLA-4

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.4, April 28, 2023

  ABSTRACT: Ovarian cancer is one of the three major malignant tumors in gynecology, with increasing incidence and mortality rates. Currently, the main treatment methods remain surgical intervention in combination with chemotherapy. However, due to its high recurrence rate and the risk of drug resistance, the overall prognosis is poor. Ovarian cancer has been identified as an immunegenic tumor, and in recent years, with the continued advancement of research into immune evasion mechanisms, immunotherapy has emerged as a groundbreaking treatment modality. This article will focus on the immune escape mechanisms and their application in ovarian cancer, providing a comprehensive overview of its current status and the challenges it faces.